Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Quoin Pharmaceuticals Ltd QNRX

Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology... see more

Recent & Breaking News (NDAQ:QNRX)

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results

GlobeNewswire November 7, 2024

Quoin Pharmaceuticals Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient

GlobeNewswire November 5, 2024

Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024

GlobeNewswire October 31, 2024

Quoin Pharmaceuticals Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome

GlobeNewswire October 22, 2024

Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO

GlobeNewswire September 9, 2024

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2024 Financial Results

GlobeNewswire August 8, 2024

Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome

GlobeNewswire August 6, 2024

Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024

GlobeNewswire August 1, 2024

Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome

GlobeNewswire June 27, 2024

Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference

GlobeNewswire June 25, 2024

Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland

GlobeNewswire June 12, 2024

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results

GlobeNewswire May 9, 2024

Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024

GlobeNewswire May 2, 2024

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results

GlobeNewswire March 13, 2024

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

GlobeNewswire March 7, 2024

Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering

GlobeNewswire March 5, 2024

Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies

GlobeNewswire March 4, 2024

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product

GlobeNewswire February 8, 2024

Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome

GlobeNewswire December 13, 2023

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results

GlobeNewswire November 8, 2023